Singapore Startup ChemT Secures $5 Million to Speed Up Affordable Biologics Production with AI
A Singapore-based AI biotech startup called ChemT has raised $5 million in fresh funding to advance its software for biologics manufacturing.
The round brings the company's total capital to $5 million, following an earlier $1 million angel investment secured within the past 18 months.
Why AI Matters for Drug Manufacturing
ChemT develops AI tools that optimize the complex process of producing biologics such as cell therapies and vaccines.
This technology helps research labs cut down on time and errors during production runs.
Improved efficiency in biologics manufacturing can eventually lower costs for treatments that currently remain expensive for many patients.
Singapore's growing support for AI and biotech startups positions the city-state as a key player in Asia's life sciences scene.
Future Outlook for Accessible Cell Therapies
ChemT aims to achieve GMP compliance soon, which would allow wider use of its platform in regulated settings.
Its software is already in use by labs across Asia, the US, Israel, and Singapore.
Founders with expertise in AI and cell therapy are driving the company's focus on immune cell manufacturing.
Broader adoption of such AI solutions could make advanced treatments more available to people worldwide in the coming years.
Overall, this development highlights how targeted AI investments support innovation that benefits everyday health outcomes.
